li001

Dostarlimab Boosts Survival in Advanced Endometrial Cancer

Treatment /

Endometrial cancer, the second most common gynecologic malignancy, is typically treated with carboplatin and paclitaxel, but outcomes remain poor. The Phase 3 RUBY trial evaluated adding the anti–PD-1 drug dostarlimab to this regimen in 494 patients with newly diagnosed advanced or recurrent disease. Dostarlimab significantly improved results: in patients with mismatch repair–deficient or MSI-high tumors, […]

Dostarlimab Boosts Survival in Advanced Endometrial Cancer Read More »

GRAPE: An AI-Powered Revolution in Opportunistic Gastric Cancer Screening

Diagnostics /

Gastric cancer (GC) is a leading cause of cancer death globally. Early diagnosis is critical, as the five-year survival rate drops from up to 99% for early-stage GC (EGC) to under 30% for advanced stages. While standard endoscopy screening has lowered mortality in some countries, it is generally too expensive and invasive for large-scale public

GRAPE: An AI-Powered Revolution in Opportunistic Gastric Cancer Screening Read More »

Tumor Bacteria Produce Molecule That Enhances Chemotherapy and Fights Cancer

Molecular Oncology /

International scientists discovered that bacteria living in tumors produce a molecule called 2-methylisocitrate (2-MiCit) that can fight cancer and enhance chemotherapy effectiveness. Through screening over 1,100 conditions using C. elegans worms, scientists found that E. coli bacteria produce 2-MiCit, which improves the effectiveness of the chemotherapy drug 5-fluorouracil (5-FU). The molecule works by inhibiting a

Tumor Bacteria Produce Molecule That Enhances Chemotherapy and Fights Cancer Read More »

Blocking EZH2 Enzyme Shows Promise in Stopping Triple-Negative Breast Cancer Spread

Research Advances /

A new Weill Cornell Medicine study suggests a promising approach to stop the spread of Triple-Negative Breast Cancer (TNBC), one of the most aggressive cancer forms. Researchers found that the enzyme EZH2 drives TNBC cells to divide abnormally, leading to chromosomal instability and enabling them to metastasize (spread to distant organs). The study, published in Cancer Discovery, found that drugs

Blocking EZH2 Enzyme Shows Promise in Stopping Triple-Negative Breast Cancer Spread Read More »

Glioblastoma Erodes Skull and Manipulates Bone Marrow to Accelerate Tumor Growth

Research Advances /

A study from Montefiore Einstein Comprehensive Cancer Center in Nature Neuroscience reveals that glioblastoma (GBM) is not just a local brain tumor but a systemic disease affecting the skull and immune system. GBM causes skull thinning, enlarging channels between the skull marrow and brain. This remodeling shifts immune balance—doubling pro-inflammatory neutrophils and nearly eliminating B cells—allowing

Glioblastoma Erodes Skull and Manipulates Bone Marrow to Accelerate Tumor Growth Read More »

Detecting Cancer Three Years Earlier with Plasma Cell-Free DNA

Diagnostics /

A study used non-interventional, prospectively collected plasma from the ARIC cohort to assess a multi-cancer early detection (MCED) strategy using circulating tumor DNA (ctDNA). This unique design allowed for the observation of cancer’s natural progression. In Phase I, analyzing “Early plasma samples” (collected ≤6 months before diagnosis) from 26 cancer cases and 26 controls, ctDNA

Detecting Cancer Three Years Earlier with Plasma Cell-Free DNA Read More »

Advancing Gynecologic Oncology: The Role of AI in Diagnostics and Treatment

Technology Innovation /

AI is revolutionizing gynecologic cancer care (cervical, ovarian, endometrial) by improving early detection, diagnosis, and treatment planning. Machine learning (ML) and deep learning (DL) enhance screening accuracy, automate workflows, and integrate complex clinical data, addressing gaps in traditional methods and increasing efficiency in EHR management and clinical trial enrollment. In screening, AI enables automated Pap

Advancing Gynecologic Oncology: The Role of AI in Diagnostics and Treatment Read More »

Conquering Aggressive Sarcoma: The Promise of Engineered T-Cells

Research Advances /

Sarcomas, a rare and aggressive category of over 100 connective tissue malignancies, present a significant challenge due to high metastasis rates and resistance to standard therapies like conventional chemotherapy and first-generation checkpoint inhibitors. A major breakthrough is occurring with Adoptive Cell Therapy (ACT), where a patient’s immune cells are genetically engineered to target cancer. Notably, the

Conquering Aggressive Sarcoma: The Promise of Engineered T-Cells Read More »

Stopping the Spread: EZH2 Inhibitors Thwart Aggressive Breast Cancer Metastasis

Targeted Therapy /

A new study from Weill Cornell Medicine reveals that the enzyme EZH2 drives chromosomal instability in triple-negative breast cancer (TNBC), promoting metastasis. Researchers found that overproduction of EZH2 silences the gene tankyrase 1, causing accumulation of CPAP and abnormal chromosome segregation during cell division. This faulty process enables cancer cells to spread aggressively to distant organs.

Stopping the Spread: EZH2 Inhibitors Thwart Aggressive Breast Cancer Metastasis Read More »

Radiation Matters: Updated Evidence on Pediatric Imaging and Cancer Risk

Technology Innovation /

Ionizing radiation from medical imaging, particularly CT scans, is a major source of radiation exposure for children in the U.S. and a known carcinogen linked to hematologic malignancies (blood cancers). The large RIC cohort study (3.7 million children in the U.S. and Canada) found a significant dose-response relationship between cumulative bone marrow radiation dose and cancer risk. A

Radiation Matters: Updated Evidence on Pediatric Imaging and Cancer Risk Read More »